Kakao Healthcare and Sanofi Sign MOU for Collaboration on Medical Data-Based RWE Demonstration Research
Part of Korea-France Economic Cooperation
Kakao Healthcare and the Korean subsidiary of global biopharmaceutical company Sanofi announced on April 6 that they had signed a Memorandum of Understanding (MOU) on the 3rd for collaboration on real-world evidence (RWE) demonstration research based on medical data and the development of AI solutions.
Kakao Healthcare and Sanofi signed a Memorandum of Understanding (MOU) on the 3rd at the KFI Tower Conference Center in Yeouido, Seoul, during the "3rd Korea-France Business Future Dialogue" for collaboration on real-world evidence (RWE) research based on medical data and the development of AI solutions. In the background, the representative of Sanofi Korea (left) and Hwee Hwang, CEO of Kakao Healthcare (right), are taking a commemorative photo after the MOU. Kakao Healthcare
View original imageThis MOU was signed during the "Korea-France Economic Future Dialogue," which was held in conjunction with French President Emmanuel Macron's visit to Korea to mark the 140th anniversary of diplomatic relations between Korea and France. The collaboration between the two companies is a meaningful case that combines Korea's digital healthcare infrastructure and technology with France's pharmaceutical and AI capabilities, presenting new possibilities for cooperation in the healthcare sector between the two countries.
Specifically, the two companies will jointly conduct RWE demonstration research based on medical data. In addition, they plan to collaborate on the development and advancement of AI models using federated learning. Through these efforts, they aim to improve patient health and contribute to the advancement of medical research.
To this end, Kakao Healthcare will provide platforms and technology capable of conducting research based on real-world clinical data. Sanofi will participate in the collaboration with its AI and digital healthcare capabilities, as well as its medical and scientific expertise.
By leveraging the data-driven research capabilities and AI technologies established through this partnership, both companies will explore applications for the early detection of diseases and personalized patient management across a variety of conditions. In particular, the collaboration will focus on developing AI-based analytics for early diagnosis in the field of Fabry disease, and on creating models to optimize personalized management and treatment in the field of asthma.
Baek Kyung-eun, CEO of Sanofi Korea, stated, "RWE is a core element of patient-centered healthcare. This collaboration, which brings together Sanofi's AI and digital healthcare capabilities with Kakao Healthcare's RWE platform technology, will take clinical evidence research to the next level and serve as a meaningful starting point for expanding into AI solution development. We hope this partnership will serve as an opportunity to further strengthen the strategic partnership between the two companies in the digital healthcare field."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Hwang Hee, CEO of Kakao Healthcare, commented, "This collaboration is highly meaningful in that it lays the foundation for implementing RWE research based on medical data in real clinical settings. Together with Sanofi, we will combine our data analysis and research capabilities to build research models applicable to real clinical practice and continuously expand the value of RWE-based research."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.